Enanta To Discontinue Internal Development Of NASH Candidates

Loading...
Loading...
  • After looking at interim phase 2b data, Enanta Pharmaceuticals Inc ENTA has decided to stop the monotherapy trial of EDP-305 for non-alcoholic steatohepatitis (NASH).
  • Instead, Enanta now plans to prioritize combination approaches through out-licensing arrangements.
  • The company has two NASH candidates, EDP-305 and EDP-297, in the clinic. Both drugs are FXR agonists.
  • Neither candidate has done enough to persuade Enanta to continue internal development.
  • Enanta is stopping the phase 2b trial of EDP-305 that began last year after an interim analysis of the 12-week data. 
  • Enanta had the option to switch its focus to its follow-up candidate. However, a Phase 1 trial suggested EDP-297 is "not substantially differentiated" from EDP-305. 
  • The phase 1 study "found the overall balance of activity and tolerability was comparable to that of EDP-305." 
  • Price Action: ENTA stock closed down by 1.26% at $60.19 on Monday.
Posted In: BiotechNewsHealth CareSmall CapMoversTrading IdeasGeneralBriefsNon Alcoholic steatohepatitisPhase 2 Trial
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...